Fibrosis Biomarker Detection Service

Fibrosis, a complex pathological process affecting multiple organs and characterized by its irreversibility, is distinguished by the excessive deposition of extracellular matrix (ECM) components such as collagen, fibronectin (FN), and alpha-smooth muscle actin (α-SMA). This accumulation leads to the transformation of fibroblasts into myofibroblasts. The excessive ECM buildup not only disrupts tissue architecture but also compromises organ functionality, ultimately culminating in organ failure and death. Consequently, fibrosis is acknowledged as a significant contributor to elevated morbidity and mortality rates in a variety of diseases. Clinical manifestations predominantly include pulmonary, renal, hepatic, and myocardial fibrosis, among others. Yet, their pathogenesis and specific therapeutic approaches remain areas of active investigation. In the aftermath of COVID-19, the pulmonary fibrosis triggered by novel coronavirus pneumonia has propelled advancements in the development of antifibrotic therapeutics. LeadQuest Biotech has developed a robust platform for the screening and evaluation of antifibrotic drugs, employing a range of methodologies including enzymology, quantitative PCR with fluorescence detection, Western blotting, immunofluorescence, ELISA, and in vivo efficacy assessment.